STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting
STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3 STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022 20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is […]
